These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21271227)

  • 1. Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.
    Meller B; Rave-Fränck M; Breunig C; Schirmer M; Baehre M; Nadrowitz R; Liersch T; Meller J
    Strahlenther Onkol; 2011 Feb; 187(2):120-6. PubMed ID: 21271227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
    Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
    J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results.
    Schoffelen R; Boerman OC; Goldenberg DM; Sharkey RM; van Herpen CM; Franssen GM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ
    Br J Cancer; 2013 Aug; 109(4):934-42. PubMed ID: 23860529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
    Schoffelen R; Sharkey RM; Goldenberg DM; Franssen G; McBride WJ; Rossi EA; Chang CH; Laverman P; Disselhorst JA; Eek A; van der Graaf WT; Oyen WJ; Boerman OC
    Mol Cancer Ther; 2010 Apr; 9(4):1019-27. PubMed ID: 20354120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
    Touchefeu Y; Bailly C; Frampas E; Eugène T; Rousseau C; Bourgeois M; Bossard C; Faivre-Chauvet A; Rauscher A; Masson D; David A; Cerato E; Carlier T; Sharkey RM; Goldenberg DM; Barbet J; Kraeber-Bodere F; Bodet-Milin C
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):874-882. PubMed ID: 32820369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
    McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
    J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and (67/68Ga)-labeled haptens by pretargeting.
    Hall H; Velikyan I; Blom E; Ulin J; Monazzam A; Påhlman L; Micke P; Wanders A; McBride W; Goldenberg DM; Långström B
    Am J Nucl Med Mol Imaging; 2012; 2(2):141-50. PubMed ID: 23133809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
    Schoffelen R; Woliner-van der Weg W; Visser EP; Goldenberg DM; Sharkey RM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1593-602. PubMed ID: 24643780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
    Karacay H; McBride WJ; Griffiths GL; Sharkey RM; Barbet J; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2000; 11(6):842-54. PubMed ID: 11087333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoembryonic antigen as a marker of radioresistance in colorectal cancer: a potential role of macrophages.
    Huang EY; Chang JC; Chen HH; Hsu CY; Hsu HC; Wu KL
    BMC Cancer; 2018 Mar; 18(1):321. PubMed ID: 29580202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
    Sharkey RM; Karacay H; Vallabhajosula S; McBride WJ; Rossi EA; Chang CH; Goldsmith SJ; Goldenberg DM
    Radiology; 2008 Feb; 246(2):497-507. PubMed ID: 18227543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients.
    Bodet-Milin C; Ferrer L; Rauscher A; Masson D; Rbah-Vidal L; Faivre-Chauvet A; Cerato E; Rousseau C; Hureaux J; Couturier O; Salaün PY; Goldenberg DM; Sharkey RM; Kraeber-Bodéré F; Barbet J
    Front Med (Lausanne); 2015; 2():84. PubMed ID: 26640780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer.
    Liu ZP; Li LM; Liu XL; Zhang DX
    Onkologie; 2012; 35(3):108-13. PubMed ID: 22414974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody.
    Aarts F; Boerman OC; Sharkey RM; Hendriks T; Chang CH; McBride WJ; Bleichrodt RP; Oyen WJ; Goldenberg DM
    Cancer; 2010 Feb; 116(4 Suppl):1111-7. PubMed ID: 20127959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
    Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
    J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
    Griffiths GL; Chang CH; McBride WJ; Rossi EA; Sheerin A; Tejada GR; Karacay H; Sharkey RM; Horak ID; Hansen HJ; Goldenberg DM
    J Nucl Med; 2004 Jan; 45(1):30-9. PubMed ID: 14734668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.
    Rossi EA; Chang CH; Losman MJ; Sharkey RM; Karacay H; McBride W; Cardillo TM; Hansen HJ; Qu Z; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7122s-7129s. PubMed ID: 16203811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
    Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.